Identification

Name
Temozolomide
Accession Number
DB00853  (APRD00557)
Type
Small Molecule
Groups
Approved, Investigational
Description

Temozolomide (Temodar and Temodal) is an oral alkylating agent used for the treatment of refractory anaplastic astrocytoma -- a type of cancerous brain tumor. Temozolomide is not active until it is converted at physiologic pH to the active form, 5-(3-methyltriazen-1-yl)imidazole-4-carboxamide (MTIC).

Structure
Thumb
Synonyms
  • 3-Methyl-4-oxo-3,4-dihydroimidazo(5,1-D)(1,2,3,5)tetrazine-8-carboxamide
  • 3,4-dihydro-3-Methyl-4-oxoimidazo(5,1-D)-1,2,3,5-tetrazine-8-carboxamide
  • 3,4-dihydro-3-Methyl-4-oxoimidazo(5,1-D)-as-tetrazine-8-carboxamide
  • 8-Carbamoyl-3-methylimidazo(5,1-D)-1,2,3,5-tetrazin-4(3H)-one
  • BRN 5547136
  • CCRG 81045
  • CCRIS 8996
  • m & b 39831
  • MB 39831
  • Methazolastone
  • NSC 362856
  • Temodal
  • Temozolodida
  • Temozolomid
  • Temozolomida
  • Témozolomide
  • Temozolomidum
  • TMZ
External IDs
BRN 5547136 / CCRG 81045 / CCRG-81045 / M & B 39831 / M&B 39831 / NSC 362856 / NSC-362856 / SCH 52365 / SCH-52365
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ach-temozolomideCapsule140 mgOralAccord Healthcare Limited2012-07-25Not applicableCanada
Ach-temozolomideCapsule100 mgOralAccord Healthcare Limited2012-07-25Not applicableCanada
Ach-temozolomideCapsule5 mgOralAccord Healthcare Limited2016-01-13Not applicableCanada
Ach-temozolomideCapsule180 mgOralAccord Healthcare Limited2012-07-25Not applicableCanada
Ach-temozolomideCapsule20 mgOralAccord Healthcare Limited2012-07-25Not applicableCanada
Ach-temozolomideCapsule250 mgOralAccord Healthcare Limited2012-07-25Not applicableCanada
Act TemozolomideCapsule180 mgOralActavis Pharma CompanyNot applicableNot applicableCanada
Act TemozolomideCapsule20 mgOralActavis Pharma Company2012-11-07Not applicableCanada
Act TemozolomideCapsule5 mgOralActavis Pharma Company2015-12-08Not applicableCanada
Act TemozolomideCapsule250 mgOralActavis Pharma Company2012-11-07Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-temozolomideCapsule100 mgOralApotex CorporationNot applicableNot applicableCanada
Apo-temozolomideCapsule250 mgOralApotex CorporationNot applicableNot applicableCanada
Apo-temozolomideCapsule5 mgOralApotex CorporationNot applicableNot applicableCanada
Apo-temozolomideCapsule140 mgOralApotex CorporationNot applicableNot applicableCanada
Apo-temozolomideCapsule20 mgOralApotex CorporationNot applicableNot applicableCanada
Apo-temozolomideCapsule180 mgOralApotex CorporationNot applicableNot applicableCanada
Emozolomide AccordCapsule100 mgOralHospira, Inc.2010-03-15Not applicableEu
Emozolomide AccordCapsule100 mgOralHospira, Inc.2010-03-15Not applicableEu
Emozolomide AccordCapsule5 mgOralHospira, Inc.2010-03-15Not applicableEu
Emozolomide AccordCapsule5 mgOralHospira, Inc.2010-03-15Not applicableEu
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
TemozolomideCapsule5 mg/1OralChemi Pharma Llc2017-11-01Not applicableUs
TemozolomideCapsule140 mg/1OralChemi Pharma Llc2017-11-01Not applicableUs
TemozolomideCapsule20 mg/1OralChemi Pharma Llc2017-11-01Not applicableUs
TemozolomideCapsule180 mg/1OralChemi Pharma Llc2017-11-01Not applicableUs
TemozolomideCapsule100 mg/1OralChemi Pharma Llc2017-11-01Not applicableUs
TemozolomideCapsule250 mg/1OralChemi Pharma Llc2017-11-01Not applicableUs
International/Other Brands
Temodar
Categories
UNII
YF1K15M17Y
CAS number
85622-93-1
Weight
Average: 194.1508
Monoisotopic: 194.055223466
Chemical Formula
C6H6N6O2
InChI Key
BPEGJWRSRHCHSN-UHFFFAOYSA-N
InChI
InChI=1S/C6H6N6O2/c1-11-6(14)12-2-8-3(4(7)13)5(12)9-10-11/h2H,1H3,(H2,7,13)
IUPAC Name
3-methyl-4-oxo-3H,4H-imidazo[4,3-d][1,2,3,5]tetrazine-8-carboxamide
SMILES
CN1N=NC2=C(N=CN2C1=O)C(N)=O

Pharmacology

Indication

For the treatment of adult patients diagnosed with anaplastic astrocytoma whose disease has progressed after therapy with nitrosourea and procarbazine, as well as concomitantly with radiation therapy for treatment of newly diagnosed glioblastoma multiforme. Also used as maintenance therapy for glioblastoma multiforme.

Structured Indications
Pharmacodynamics

Temozolomide is an imidazotetrazine deritave and an antineoplastic agent. It is a prodrug that has little to no pharmacological activity until it is hydrolyzed in vivo to 5-(3-methyltriazen-1-yl)imidazole-4-carboxamide (MTIC). After administration, temozolomide undergoes rapid, nonenzymatic hydrolysis at physiological pH to MTIC, which is the active form of the drug. MTIC is generated through the effect of water at the highly electropositive C4 position of temozolomide, causing the ring of temozolomide to open, release carbon dioxide, and generate MTIC.

Mechanism of action

Temozolomide is not active until it is converted at physiologic pH to MTIC. It is suggested that MTIC then alkylates DNA at the N7 position of guanine, O3 position of adenosine, and O6 position of guanosine, with the most common site being the N7 position. This methylation of guanine residues lead to single and double-strand DNA breaks and subsequent apoptotic cell death. It is suggested that the N7-methylguanine plays a critical role in the antitumor activity of the drug, as there is a correlation between the sensitivity of tumor cell lines to temozolomide and the activity of O6-alkylguanine alkyltransferase, which is the DNA repair protein that specifically removes alkyl groups at the O6 position of guanine. Cells lines that have lower levels of AGT are more sensitive to the cytotoxicity of temozolomide. It is also suggested that cytotoxic mechanism of temozolomide is related to the failure of the DNA MMR system to find a complementary base for methylated guanine. The DNA MMR system is involved in the formation of a number of proteins that remove methylated guanine. Evidence shows that when this repair process is targeted to the DNA strand opposite the O6-methylguanine, its inability to find the correct target leads to long-lived nicks in the DNA. The accumulation of these nicks lead to the inhibition of replication in the daughter cells, thereby blocking the cell cycle at the G2-M boundary.

TargetActionsOrganism
ADNA
cross-linking/alkylation
Human
Absorption

Rapid and complete absorption in the gastrointestinal tract

Volume of distribution
  • 0.4 L/kg
Protein binding

15%

Metabolism
Not Available
Route of elimination

About 38% of the administered temozolomide total radioactive dose is recovered over 7 days: 37.7% in urine and 0.8% in feces.

Half life

Approximately 1.8 hours.

Clearance
  • 5.5 L/hr/m2
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Temozolomide.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Temozolomide.Experimental
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Temozolomide.Approved, Investigational
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Temozolomide.Investigational
BevacizumabBevacizumab may increase the cardiotoxic activities of Temozolomide.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Temozolomide.Approved
Clostridium tetani toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Temozolomide.Approved
ClozapineThe risk or severity of adverse effects can be increased when Temozolomide is combined with Clozapine.Approved
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Temozolomide.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Temozolomide.Approved, Investigational
CymarinCymarin may decrease the cardiotoxic activities of Temozolomide.Experimental
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Temozolomide.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Temozolomide.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Temozolomide.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Temozolomide.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Temozolomide.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Temozolomide.Approved, Investigational
FingolimodTemozolomide may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
G17DTThe therapeutic efficacy of G17DT can be decreased when used in combination with Temozolomide.Investigational
GI-5005The therapeutic efficacy of GI-5005 can be decreased when used in combination with Temozolomide.Investigational
GitoformateGitoformate may decrease the cardiotoxic activities of Temozolomide.Experimental
Hepatitis A VaccineThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Temozolomide.Approved
Hepatitis B Vaccine (Recombinant)The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Temozolomide.Approved, Withdrawn
INGN 201The therapeutic efficacy of INGN 201 can be decreased when used in combination with Temozolomide.Investigational
INGN 225The therapeutic efficacy of INGN 225 can be decreased when used in combination with Temozolomide.Investigational
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Temozolomide.Experimental
LeflunomideThe risk or severity of adverse effects can be increased when Temozolomide is combined with Leflunomide.Approved, Investigational
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Temozolomide.Investigational, Withdrawn
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Temozolomide.Experimental
NatalizumabThe risk or severity of adverse effects can be increased when Temozolomide is combined with Natalizumab.Approved, Investigational
OleandrinOleandrin may decrease the cardiotoxic activities of Temozolomide.Experimental, Investigational
OuabainOuabain may decrease the cardiotoxic activities of Temozolomide.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Temozolomide.Approved, Vet Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Temozolomide.Experimental
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Temozolomide.Approved, Investigational
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Temozolomide.Experimental
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when Temozolomide is combined with Rabies virus inactivated antigen, A.Approved
Rabies virus inactivated antigen, AThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Temozolomide.Approved
RindopepimutThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Temozolomide.Investigational
RoflumilastRoflumilast may increase the immunosuppressive activities of Temozolomide.Approved
Rotavirus VaccineThe therapeutic efficacy of Rotavirus Vaccine can be decreased when used in combination with Temozolomide.Approved
Rubella virus vaccineThe therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Temozolomide.Approved
Salmonella typhi ty21a live antigenThe therapeutic efficacy of Salmonella typhi ty21a live antigen can be decreased when used in combination with Temozolomide.Approved
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Temozolomide.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Temozolomide.Approved
SRP 299The therapeutic efficacy of SRP 299 can be decreased when used in combination with Temozolomide.Investigational
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Temozolomide.Approved, Investigational
TecemotideThe therapeutic efficacy of Tecemotide can be decreased when used in combination with Temozolomide.Investigational
TG4010The therapeutic efficacy of TG4010 can be decreased when used in combination with Temozolomide.Investigational
TofacitinibTemozolomide may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Temozolomide.Approved, Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Temozolomide.Approved, Investigational
Yellow fever vaccineThe therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Temozolomide.Approved
Zoster vaccineThe therapeutic efficacy of Zoster vaccine can be decreased when used in combination with Temozolomide.Approved
Food Interactions
Not Available

References

Synthesis Reference

Shen-Chun Kuo, "Synthesis of temozolomide and analogs." U.S. Patent US20020133006, issued September 19, 2002.

US20020133006
General References
  1. Neyns B, Tosoni A, Hwu WJ, Reardon DA: Dose-dense temozolomide regimens: antitumor activity, toxicity, and immunomodulatory effects. Cancer. 2010 Jun 15;116(12):2868-77. doi: 10.1002/cncr.25035. [PubMed:20564393]
  2. Wick W, Platten M, Weller M: New (alternative) temozolomide regimens for the treatment of glioma. Neuro Oncol. 2009 Feb;11(1):69-79. doi: 10.1215/15228517-2008-078. Epub 2008 Sep 4. [PubMed:18772354]
  3. Villano JL, Seery TE, Bressler LR: Temozolomide in malignant gliomas: current use and future targets. Cancer Chemother Pharmacol. 2009 Sep;64(4):647-55. doi: 10.1007/s00280-009-1050-5. Epub 2009 Jun 19. [PubMed:19543728]
  4. Meije Y, Lizasoain M, Garcia-Reyne A, Martinez P, Rodriguez V, Lopez-Medrano F, Juan RS, Lalueza A, Aguado JM: Emergence of cytomegalovirus disease in patients receiving temozolomide: report of two cases and literature review. Clin Infect Dis. 2010 Jun 15;50(12):e73-6. doi: 10.1086/653011. [PubMed:20455691]
  5. Trinh VA, Patel SP, Hwu WJ: The safety of temozolomide in the treatment of malignancies. Expert Opin Drug Saf. 2009 Jul;8(4):493-9. doi: 10.1517/14740330902918281 . [PubMed:19435405]
  6. Yung WK: Temozolomide in malignant gliomas. Semin Oncol. 2000 Jun;27(3 Suppl 6):27-34. [PubMed:10866347]
  7. Friedman HS, Kerby T, Calvert H: Temozolomide and treatment of malignant glioma. Clin Cancer Res. 2000 Jul;6(7):2585-97. [PubMed:10914698]
  8. Mutter N, Stupp R: Temozolomide: a milestone in neuro-oncology and beyond? Expert Rev Anticancer Ther. 2006 Aug;6(8):1187-204. [PubMed:16925485]
External Links
Human Metabolome Database
HMDB14991
KEGG Drug
D06067
PubChem Compound
5394
PubChem Substance
46507934
ChemSpider
5201
BindingDB
50034562
ChEBI
72564
ChEMBL
CHEMBL810
Therapeutic Targets Database
DAP000987
PharmGKB
PA451609
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Temozolomide
ATC Codes
L01AX03 — Temozolomide
AHFS Codes
  • 10:00.00 — Antineoplastic Agents
FDA label
Download (67.2 KB)
MSDS
Download (58 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0Active Not RecruitingTreatmentDesmoplastic Small Round Cell Tumor (DSRCT) / Sarcomas1
0Active Not RecruitingTreatmentDiffuse Intrinsic Pontine Glioma (DIPG) / Newly Diagnosed High-Grade Gliomas1
0Active Not RecruitingTreatmentGlioblastomas1
0RecruitingDiagnosticBlood Brain Barrier Defect1
0RecruitingOtherGlioblastoma Multiforme1
0RecruitingTreatmentGrade II/III Glioma1
0RecruitingTreatmentHigh Grade Glioma (HGG)1
0RecruitingTreatmentNeuroblastoma (NB)1
0WithdrawnTreatmentAstrocytomas / Brain Stem Gliomas / Ependymomas / Mixed Gliomas / Oligodendrogliomas / Optic Nerve Glioma1
1Active Not RecruitingTreatmentAccelerated Phase of Disease / Acute Lymphoblastic Leukaemias (ALL) / Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome / Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 / Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11 / Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1 / Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1 / Adult Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A / Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL / Adult Acute Promyelocytic Leukemia With PML-RARA / Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA / Adult B Acute Lymphoblastic Leukemia / Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 / Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 / Adult T Acute Lymphoblastic Leukemia / Alkylating Agent-Related Acute Myeloid Leukemia / Blastic Phase / Chronic Myelomonocytic Leukemia / Leukemia Acute Myeloid Leukemia (AML) / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Disease / Secondary Acute Myeloid Leukemia / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Adult Acute Myeloid Leukemia1
1Active Not RecruitingTreatmentAdult Anaplastic Astrocytoma / Adult Anaplastic Oligodendroglioma / Adult Giant Cell Glioblastoma / Adult Glioblastoma / Adult Gliosarcoma / Adult Mixed Glioma / Recurrent Adult Brain Neoplasm1
1Active Not RecruitingTreatmentAdult Brain Glioblastoma / Adult Giant Cell Glioblastoma / Adult Gliosarcoma1
1Active Not RecruitingTreatmentAnaplastic Astrocytoma (AA) / Glioblastoma Multiforme1
1Active Not RecruitingTreatmentBrain Cancer1
1Active Not RecruitingTreatmentBrain and Central Nervous System Tumors1
1Active Not RecruitingTreatmentCancer, Advanced / Tumors, Solid1
1Active Not RecruitingTreatmentChildhood Solid Neoplasm / Recurrent Central Nervous System Neoplasm / Recurrent Solid Neoplasm / Refractory Central Nervous System Neoplasm1
1Active Not RecruitingTreatmentGBM / Glioblastoma Multiforme / Glioblastomas1
1Active Not RecruitingTreatmentGlioblastoma Multiforme / Gliosarcoma / Neoplasms, Brain1
1Active Not RecruitingTreatmentGlioblastomas1
1Active Not RecruitingTreatmentGlioblastomas / Gliosarcoma / Supratentorial Glioblastoma1
1Active Not RecruitingTreatmentMetastatic Cancers / Unspecified Adult Solid Tumor1
1Active Not RecruitingTreatmentMetastatic Melanoma1
1Active Not RecruitingTreatmentNeuroblastomas1
1Active Not RecruitingTreatmentNewly Diagnosed High Grade Glioma1
1Active Not RecruitingTreatmentRectal Carcinoma1
1Active Not RecruitingTreatmentSolid Tumors, Glioblastoma, Recurrent Malignant Gliomas1
1CompletedTreatmentAcoustic Schwannoma / Adult Anaplastic (Malignant) Meningioma / Adult Anaplastic Astrocytoma / Adult Anaplastic Ependymoma / Adult Brain Stem Glioma / Adult Choroid Plexus Neoplasm / Adult Craniopharyngioma / Adult Diffuse Astrocytoma / Adult Ependymoblastoma / Adult Ependymoma / Adult Giant Cell Glioblastoma / Adult Glioblastoma / Adult Gliosarcoma / Adult Grade I Meningioma / Adult Grade II Meningioma / Adult Medulloblastoma / Adult Mixed Glioma / Adult Myxopapillary Ependymoma / Adult Oligodendroglioma / Adult Papillary Meningioma / Adult Pilocytic Astrocytoma / Adult Pineal Gland Astrocytoma / Adult Pineoblastoma / Adult Pineocytoma / Adult Primary Melanocytic Lesion of Meninges / Adult Subependymal Giant Cell Astrocytoma / Adult Subependymoma / Adult Supratentorial Primitive Neuroectodermal Tumor / Malignant Adult Intracranial Hemangiopericytoma1
1CompletedTreatmentAdult Anaplastic Astrocytoma / Adult Anaplastic Oligodendroglioma / Adult Giant Cell Glioblastoma / Adult Glioblastoma / Adult Gliosarcoma / Adult Mixed Glioma / Recurrent Adult Brain Tumor1
1CompletedTreatmentAdult Giant Cell Glioblastoma / Adult Glioblastoma / Adult Gliosarcoma3
1CompletedTreatmentAdvanced Solid Tumors1
1CompletedTreatmentAnaplastic Astrocytoma (AA) / Glioblastomas / Gliosarcoma2
1CompletedTreatmentAstrocytomas / Ependymomas / Medulloblastomas / PNET / Pontine Glioma1
1CompletedTreatmentBrain and Central Nervous System Tumors11
1CompletedTreatmentBrain and Central Nervous System Tumors / Cancer, Ovarian / Childhood Germ Cell Tumor / Extragonadal Germ Cell Tumor / Liver Cancer / Neuroblastomas / Renal Cancers / Sarcomas / Unspecified Childhood Solid Tumor, Protocol Specific1
1CompletedTreatmentBrain and Central Nervous System Tumors / Cancer, Ovarian / Childhood Germ Cell Tumor / Liver Cancer / Neuroblastomas / Renal Cancers / Sarcomas / Unspecified Childhood Solid Tumor, Protocol Specific1
1CompletedTreatmentBrain and Central Nervous System Tumors / Malignant Lymphomas / Metastatic Cancers / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentBrain and Central Nervous System Tumors / Unspecified Childhood Solid Tumor, Protocol Specific1
1CompletedTreatmentCancer, Breast / Cancer, Ovarian / Fallopian Tube Cancer / Hepatocellular,Carcinoma / Metastatic Melanoma / Non-hematologic Malignancies / Primary Peritoneal Cancer1
1CompletedTreatmentCancers / Chronic Lung Diseases1
1CompletedTreatmentChildhood Atypical Teratoid/Rhabdoid Tumor / Childhood Central Nervous System Choriocarcinoma / Childhood Central Nervous System Embryonal Tumor / Childhood Central Nervous System Germinoma / Childhood Central Nervous System Mixed Germ Cell Tumor / Childhood Central Nervous System Teratoma / Childhood Central Nervous System Yolk Sac Tumor / Childhood Choroid Plexus Tumor / Childhood Craniopharyngioma / Childhood Ependymoblastoma / Childhood Grade I Meningioma / Childhood Grade II Meningioma / Childhood Grade III Meningioma / Childhood High-grade Cerebellar Astrocytoma / Childhood High-grade Cerebral Astrocytoma / Childhood Infratentorial Ependymoma / Childhood Low-grade Cerebellar Astrocytoma / Childhood Low-grade Cerebral Astrocytoma / Childhood Medulloepithelioma / Childhood Mixed Glioma / Childhood Oligodendroglioma / Childhood Supratentorial Ependymoma / Extra-Adrenal Paraganglioma / Recurrent Childhood Brain Stem Glioma / Recurrent Childhood Central Nervous System Embryonal Tumor / Recurrent Childhood Cerebellar Astrocytoma / Recurrent Childhood Cerebral Astrocytoma / Recurrent Childhood Ependymoma / Recurrent Childhood Medulloblastoma / Recurrent Childhood Pineoblastoma / Recurrent Childhood Spinal Cord Neoplasm / Recurrent Childhood Subependymal Giant Cell Astrocytoma / Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor / Recurrent Childhood Visual Pathway and Hypothalamic Glioma1
1CompletedTreatmentChildhood Atypical Teratoid/Rhabdoid Tumor / Childhood Central Nervous System Germ Cell Tumor / Childhood Choroid Plexus Tumor / Childhood Craniopharyngioma / Childhood Ependymoblastoma / Childhood Grade I Meningioma / Childhood Grade II Meningioma / Childhood Grade III Meningioma / Childhood High-grade Cerebellar Astrocytoma / Childhood High-grade Cerebral Astrocytoma / Childhood Infratentorial Ependymoma / Childhood Low-grade Cerebellar Astrocytoma / Childhood Low-grade Cerebral Astrocytoma / Childhood Medulloepithelioma / Childhood Mixed Glioma / Childhood Oligodendroglioma / Childhood Supratentorial Ependymoma / Recurrent Childhood Brain Stem Glioma / Recurrent Childhood Brain Tumor / Recurrent Childhood Cerebellar Astrocytoma / Recurrent Childhood Cerebral Astrocytoma / Recurrent Childhood Ependymoma / Recurrent Childhood Medulloblastoma / Recurrent Childhood Pineoblastoma / Recurrent Childhood Spinal Cord Neoplasm / Recurrent Childhood Subependymal Giant Cell Astrocytoma / Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor / Recurrent Childhood Visual Pathway and Hypothalamic Glioma1
1CompletedTreatmentChildhood Central Nervous System Germ Cell Tumor / Childhood Choroid Plexus Tumor / Childhood Craniopharyngioma / Childhood Ependymoblastoma / Childhood Grade I Meningioma / Childhood Grade II Meningioma / Childhood Grade III Meningioma / Childhood High-grade Cerebellar Astrocytoma / Childhood High-grade Cerebral Astrocytoma / Childhood Infratentorial Ependymoma / Childhood Low-grade Cerebellar Astrocytoma / Childhood Low-grade Cerebral Astrocytoma / Childhood Medulloepithelioma / Childhood Mixed Glioma / Childhood Oligodendroglioma / Childhood Supratentorial Ependymoma / Recurrent Childhood Brain Stem Glioma / Recurrent Childhood Cerebellar Astrocytoma / Recurrent Childhood Cerebral Astrocytoma / Recurrent Childhood Ependymoma / Recurrent Childhood Medulloblastoma / Recurrent Childhood Pineoblastoma / Recurrent Childhood Subependymal Giant Cell Astrocytoma / Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor / Recurrent Childhood Visual Pathway and Hypothalamic Glioma1
1CompletedTreatmentDiarrhea / Drug/Agent Toxicity by Tissue/Organ / Neuroblastomas1
1CompletedTreatmentGiant Cell Glioblastoma / Glioblastomas / Gliosarcoma1
1CompletedTreatmentGlioblastoma Multiforme3
1CompletedTreatmentGlioblastoma Multiforme/Anaplastic Astrocytoma1
1CompletedTreatmentGlioblastoma Multiforme / Malignant Gliomas / Mixed Gliomas1
1CompletedTreatmentGlioblastoma Multiforme / Melanoma / Recurrence of Solid Tumor1
1CompletedTreatmentGlioblastomas5
1CompletedTreatmentGlioblastomas / Gliosarcoma3
1CompletedTreatmentHER2 Positive / Metastatic Brain Tumors / Metastatic Breast Cancer (MBC)1
1CompletedTreatmentLeukemias2
1CompletedTreatmentMalignant Neoplasms of Brain1
1CompletedTreatmentMelanoma2
1CompletedTreatmentMelanoma / Neoplasms, Brain1
1CompletedTreatmentMetastatic Brain Tumors / Primary Brain Tumors1
1CompletedTreatmentMetastatic Melanoma1
1CompletedTreatmentNeoplasms Malignant / Refractory Tumors1
1CompletedTreatmentNeoplasms, Brain / Tumors, Central Nervous System1
1CompletedTreatmentPreviously Treated Childhood Rhabdomyosarcoma / Recurrent Childhood Brain Tumor / Recurrent Childhood Cerebellar Astrocytoma / Recurrent Childhood Cerebral Astrocytoma / Recurrent Childhood Ependymoma / Recurrent Childhood Malignant Germ Cell Tumor / Recurrent Childhood Medulloblastoma / Recurrent Childhood Rhabdomyosarcoma / Recurrent Childhood Soft Tissue Sarcoma / Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor / Recurrent Neuroblastoma / Recurrent Osteosarcoma1
1CompletedTreatmentProstate Cancer1
1CompletedTreatmentRefractory Solid Tumors in Children1
1CompletedTreatmentTumors1
1CompletedTreatmentTumors, Central Nervous System1
1CompletedTreatmentTumors, Solid2
1CompletedTreatmentUnspecified Adult Solid Tumor, Protocol Specific5
1CompletedTreatmentUnspecified Childhood Solid Tumor, Protocol Specific1
1Not Yet RecruitingTreatmentAstrocytoma, Grade III / Glioblastomas1
1Not Yet RecruitingTreatmentGlioblastoma Multiforme (Grade IV) of Cerebellum1
1Not Yet RecruitingTreatmentMalignant Glioma of Brain1
1RecruitingTreatmentAnaplastic Oligodendroglioma (AO) / Glioblastomas / Oligodendrogliomas1
1RecruitingTreatmentAstrocytoma, Grade IV / Glioblastomas1
1RecruitingTreatmentBrain Cancer / Brain Neoplasm, Primary / Brain Neoplasms, Recurrent / Cancer of the Brain / Neoplasms, Brain1
1RecruitingTreatmentBrain and Central Nervous System Tumors1
1RecruitingTreatmentCancers / Neoplasms / Neuroendocrine Tumors / Tumors1
1RecruitingTreatmentChildhood Solid Tumors1
1RecruitingTreatmentEpendymomas / Glioblastoma Multiforme / Gliomas / Gliosarcoma / Malignant Brain Tumors / Medulloblastomas1
1RecruitingTreatmentEwing's Sarcoma (ES)2
1RecruitingTreatmentGlioblastoma Multiforme1
1RecruitingTreatmentGlioblastoma Multiforme / Glioblastomas1
1RecruitingTreatmentGlioblastoma Multiforme / Glioblastomas / Malignant Gliomas1
1RecruitingTreatmentGlioblastoma Multiforme / Gliomas1
1RecruitingTreatmentGlioblastoma, Adult1
1RecruitingTreatmentGlioblastomas2
1RecruitingTreatmentGlioblastomas / Malignant Gliomas1
1RecruitingTreatmentPrimary Brain Tumors / Tumors, Solid1
1RecruitingTreatmentRecurrent Central Nervous System Neoplasm / Recurrent Lymphoma / Recurrent Malignant Solid Neoplasm / Refractory Central Nervous System Neoplasm / Refractory Lymphomas / Refractory Malignant Solid Neoplasm1
1RecruitingTreatmentSarcomas1
1SuspendedTreatmentAdult Glioblastoma / Recurrent Adult Brain Neoplasm / Recurrent Glioblastoma1
1SuspendedTreatmentGlioblastoma Multiforme1
1TerminatedTreatmentAnaplastic Astrocytoma (AA) / Anaplastic Oligoastrocytoma / Anaplastic Oligodendroglioma (AO) / Glioblastomas / Gliosarcoma1
1TerminatedTreatmentAstrocytoma, Grade IV / Glioblastoma Multiforme1
1TerminatedTreatmentBone Cancer / Kidney Tumors / Neoplasms / Neuroblastomas / Tumors, Solid1
1TerminatedTreatmentBrain Diseases / CNS Disease / Glioblastomas1
1TerminatedTreatmentBrain and Central Nervous System Tumors1
1TerminatedTreatmentBrain and Central Nervous System Tumors / Malignant Lymphomas / Unspecified Adult Solid Tumor, Protocol Specific1
1TerminatedTreatmentCentral Nervous System Neoplasms / Neoplasms Metastasis1
1TerminatedTreatmentGlioblastoma Multiforme1
1TerminatedTreatmentLeptomeningeal Metastases1
1TerminatedTreatmentMelanoma2
1TerminatedTreatmentMetastatic Brain Tumors1
1TerminatedTreatmentNeoplasms1
1Unknown StatusTreatmentBrain and Central Nervous System Tumors2
1Unknown StatusTreatmentGlioblastoma Multiforme1
1Unknown StatusTreatmentMelanoma1
1Unknown StatusTreatmentMelanoma (Skin)2
1WithdrawnTreatmentFunctional Pancreatic Neuroendocrine Tumor / Malignant Somatostatinoma / Metastatic Adrenal Gland Pheochromocytoma / Metastatic Carcinoid Tumors / Multiple Endocrine Neoplasia Type 1 / Multiple Endocrine Neoplasia Type 2a / Multiple Endocrine Neoplasia Type 2B / Neuroendocrine Carcinoma of the Skin / Neuroendocrine Neoplasms / Non-Functional Pancreatic Neuroendocrine Tumor / Pancreatic Glucagonoma / Pancreatic Insulinoma / Recurrent Adrenal Cortex Carcinoma / Recurrent Adrenal Gland Pheochromocytoma / Recurrent Merkel Cell Carcinoma / Somatostatin-Producing Neuroendocrine Tumor / Stage III Adrenal Cortex Carcinoma / Stage III Thyroid Gland Medullary Carcinoma / Stage IIIA Merkel Cell Carcinoma / Stage IIIB Merkel Cell Carcinoma / Stage IV Adrenal Cortex Carcinoma / Stage IV Merkel Cell Carcinoma / Stage IVA Thyroid Gland Medullary Carcinoma / Stage IVB Thyroid Gland Medullary Carcinoma / Stage IVC Thyroid Gland Medullary Carcinoma / Thymic Carcinoid Tumor / VIP-Producing Neuroendocrine Tumor / Well Differentiated Adrenal Cortex Carcinoma / Zollinger-Ellison Syndrome1
1WithdrawnTreatmentGlioblastoma Multiforme1
1WithdrawnTreatmentUnspecified Adult Solid Tumor, Protocol Specific1
1, 2Active Not RecruitingTreatmentAdult Ependymoblastoma / Adult Giant Cell Glioblastoma / Adult Glioblastoma / Adult Gliosarcoma / Adult Medulloblastoma / Adult Mixed Glioma / Adult Oligodendroglial Tumors / Adult Pineoblastoma / Adult Supratentorial Primitive Neuroectodermal Tumor (PNET)1
1, 2Active Not RecruitingTreatmentAdult Giant Cell Glioblastoma / Adult Glioblastoma / Adult Gliosarcoma / Cognitive Side Effects of Cancer Therapy / Cognitive/Functional Effects1
1, 2Active Not RecruitingTreatmentAdult Glioblastoma1
1, 2Active Not RecruitingTreatmentAdult Glioblastoma / Adult Gliosarcoma / Glioblastomas / Gliosarcoma1
1, 2Active Not RecruitingTreatmentAdvanced Melanoma / Melanoma1
1, 2Active Not RecruitingTreatmentAnaplastic Astrocytoma (AA) / Brain Stem Gliomas / Childhood Mixed Glioma / Fibrillary Astrocytoma / Giant Cell Glioblastoma / Glioblastomas / Gliosarcoma / Untreated Childhood Anaplastic Astrocytoma / Untreated Childhood Brain Stem Glioma / Untreated Childhood Fibrillary Astrocytoma / Untreated Childhood Giant Cell Glioblastoma / Untreated Childhood Glioblastoma / Untreated Childhood Gliosarcoma1
1, 2Active Not RecruitingTreatmentAnaplastic Gliomas / Glioblastoma Multiforme1
1, 2Active Not RecruitingTreatmentBrain and Central Nervous System Tumors5
1, 2Active Not RecruitingTreatmentCancer of Brain and Nervous System / Glioblastoma Multiforme / Glioblastomas1
1, 2Active Not RecruitingTreatmentGlioblastoma Multiforme / Gliosarcoma1
1, 2Active Not RecruitingTreatmentMalignant Gliomas1
1, 2Active Not RecruitingTreatmentMetastatic Melanoma1
1, 2Active Not RecruitingTreatmentNeuroblastomas1
1, 2Active Not RecruitingTreatmentPatients With Newly Diagnosed Glioblastoma1
1, 2Active Not RecruitingTreatmentProgressive Neuroendocrine Tumors of pancreatic origin1
1, 2CompletedTreatmentAdult Giant Cell Glioblastoma / Adult Glioblastoma / Adult Gliosarcoma3
1, 2CompletedTreatmentBrain and Central Nervous System Tumors3
1, 2CompletedTreatmentBrain and Central Nervous System Tumors / Cancer, Ovarian / Childhood Germ Cell Tumor / Head and Neck Carcinoma / Neuroblastomas / Renal Cancers / Sarcomas / Testicular germ cell tumour1
1, 2CompletedTreatmentBrain and Central Nervous System Tumors / Malignant Lymphomas1
1, 2CompletedTreatmentEwing's Sarcoma (ES)1
1, 2CompletedTreatmentGlioblastoma Multiforme1
1, 2CompletedTreatmentGlioblastoma Multiforme / Glioblastomas / Gliosarcoma1
1, 2CompletedTreatmentGlioblastomas / Neoplasms, Brain1
1, 2CompletedTreatmentGliomas1
1, 2CompletedTreatmentIntraocular Melanoma / Melanoma (Skin)1
1, 2CompletedTreatmentMalignant Melanoma1
1, 2CompletedTreatmentMelanoma1
1, 2CompletedTreatmentMetastatic Brain Tumors / Neoplasms, Brain1
1, 2CompletedTreatmentMetastatic Cancers1
1, 2CompletedTreatmentMetastatic Melanoma3
1, 2CompletedTreatmentRecurrent Melanoma / Stage IV Skin Melanoma1
1, 2Not Yet RecruitingNot AvailableCytokine-Induced Killer Cells / Milignant Gliomas1
1, 2Not Yet RecruitingPreventionLung Cancer Non-Small Cell Cancer (NSCLC)1
1, 2RecruitingTreatmentActivation of the Sonic Hedgehog (SHH) Pathway / Histologically Confirmed Medulloblastoma1
1, 2RecruitingTreatmentAdult Glioblastoma1
1, 2RecruitingTreatmentAdult Solid Neoplasm / Childhood Solid Neoplasm / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Central Nervous System Neoplasm / Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor / Recurrent Malignant Solid Neoplasm / Refractory Central Nervous System Neoplasm1
1, 2RecruitingTreatmentAnaplastic Astrocytoma (AA) / Brain Stem Gliomas / Diffuse Intrinsic Pontine Glioma (DIPG) / DIPG / Glioblastoma Multiforme / Glioma, Astrocytic / Gliosarcoma / Low-Grade Gliomas / Optic Nerve Glioma / Pilocytic Astrocytoma / Pilomyxoid Astrocytoma / Pleomorphic Xanthoastrocytoma1
1, 2RecruitingTreatmentAstrocytomas / Astroglioma / Glioblastomas / Gliosarcoma / Neoplasms, Brain1
1, 2RecruitingTreatmentBrain Cancer / Brain Metastasis / Cancer, Breast1
1, 2RecruitingTreatmentBrain and Central Nervous System Tumors1
1, 2RecruitingTreatmentChildren, Adolescents and Young Adults With Refractory or Recurrent Malignancies1
1, 2RecruitingTreatmentGlioblastoma Multiforme1
1, 2RecruitingTreatmentGlioblastoma Multiforme / Gliomas / Gliosarcoma / Malignant Brain Tumors1
1, 2RecruitingTreatmentGlioblastomas3
1, 2RecruitingTreatmentGlioblastomas / Gliosarcoma1
1, 2RecruitingTreatmentGlioblastomas / Gliosarcoma / Malignant Neoplasms of Eye Brain and Other Parts of Central Nervous System1
1, 2RecruitingTreatmentHigh Grade Glioma, Glioblastoma1
1, 2RecruitingTreatmentLocally Advanced or Metastatic Solid Tumors1
1, 2RecruitingTreatmentLung Cancer Small Cell Lung Cancer (SCLC)1
1, 2RecruitingTreatmentMalignant Gliomas / PARP Inhibitor / Radiotherapy1
1, 2RecruitingTreatmentPancreatic Alpha Cell Carcinoma / Pancreatic Beta Islet Cell Carcinoma / Pancreatic Delta Cell Carcinoma / Pancreatic G-cell Carcinoma / Recurrent Islet Cell Carcinoma1
1, 2TerminatedTreatmentAstrocytomas / Glioblastoma Multiforme / Gliomas / Neoplasms, Brain1
1, 2TerminatedTreatmentBrain Cancer / Glioblastoma Multiforme1
1, 2TerminatedTreatmentBrain and Central Nervous System Tumors / Melanoma / Tumors, Solid1
1, 2TerminatedTreatmentGlioblastoma Multiforme1
1, 2TerminatedTreatmentGlioblastomas (GBM)1
1, 2TerminatedTreatmentMelanoma1
1, 2TerminatedTreatmentMetastatic Malignant Melanoma2
1, 2TerminatedTreatmentMetastatic Melanoma1
1, 2TerminatedTreatmentNeuroblastomas1
1, 2Unknown StatusTreatmentBrain and Central Nervous System Tumors2
1, 2Unknown StatusTreatmentGlioblastoma Multiforme3
1, 2Unknown StatusTreatmentMelanoma (Skin)1
1, 2WithdrawnTreatmentBrain and Central Nervous System Tumors1
1, 2WithdrawnTreatmentMetastatic Brain Tumors / Metastatic Melanoma1
2Active Not RecruitingTreatmentAcute Myeloid Leukemia With 11q23-abnormality in Relapse1
2Active Not RecruitingTreatmentAdult Anaplastic Astrocytoma / Adult Anaplastic Ependymoma / Adult Anaplastic Oligodendroglioma / Adult Giant Cell Glioblastoma / Adult Glioblastoma1
2Active Not RecruitingTreatmentAdult Brain Glioblastoma1
2Active Not RecruitingTreatmentAnaplastic Glioma of Brain / Loss of Chromosomes 1p/19q1
2Active Not RecruitingTreatmentBRCA1 Gene Mutation / Brca2 Gene Mutation / Cancer, Breast / Metastatic Breast Cancer (MBC)1
2Active Not RecruitingTreatmentBrain and Central Nervous System Tumors5
2Active Not RecruitingTreatmentCarcinoma, Islet Cell / Gastrinoma / Glucagonoma / Insulinoma / Pancreatic Polypeptide Tumor / Recurrent Islet Cell Carcinoma / Somatostatinoma1
2Active Not RecruitingTreatmentCarcinoma, Small Cell1
2Active Not RecruitingTreatmentDesmoplastic Small Round Cell Tumor (DSRCT) / Ewing Sarcoma of Bone or Soft Tissue / Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor / Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor1
2Active Not RecruitingTreatmentDiffuse Intrinsic Pontine Glioma (DIPG)1
2Active Not RecruitingTreatmentEwing's Sarcoma (ES)1
2Active Not RecruitingTreatmentGastrinoma / Glucagonoma / Insulinoma / Pancreatic Polypeptide Tumor / Recurrent Islet Cell Carcinoma / Recurrent Pancreatic Cancer / Somatostatinoma / Stage III Pancreatic Cancer / Stage IV Pancreatic Cancer1
2Active Not RecruitingTreatmentGiant Cell Glioblastoma / Glioblastomas / Gliosarcoma1
2Active Not RecruitingTreatmentGlioblastoma Multiforme2
2Active Not RecruitingTreatmentGlioblastoma Multiforme / Glioblastomas / Gliosarcoma / Malignant Gliomas1
2Active Not RecruitingTreatmentGlioblastoma Multiforme / Gliosarcoma1
2Active Not RecruitingTreatmentGlioblastomas / Gliosarcoma / Grade 4 Malignant Glioma / Malignant Gliomas1
2Active Not RecruitingTreatmentGliomas / High Grade Glioma (HGG)1
2Active Not RecruitingTreatmentIris Melanoma / Medium/Large Size Posterior Uveal Melanoma / Ocular Melanoma With Extraocular Extension / Recurrent Uveal Melanoma / Small Size Posterior Uveal Melanoma / Stage IV Uveal Melanoma1
2Active Not RecruitingTreatmentMalignant Melanoma2
2Active Not RecruitingTreatmentMetastatic Breast Cancer (MBC)1
2Active Not RecruitingTreatmentNeoplasms, Brain / Spinal Cord Tumors1
2Active Not RecruitingTreatmentNeoplasms, Brain / Tumors, Central Nervous System2
2Active Not RecruitingTreatmentNeuroblastomas1
2Active Not RecruitingTreatmentNeurofibromatosis 11
2Active Not RecruitingTreatmentRecurrent Childhood Medulloblastoma / Recurrent Childhood Pineoblastoma / Recurrent Childhood Supratentorial Embryonal Tumor, Not Otherwise Specified / Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor1
2Active Not RecruitingTreatmentRecurrent Melanoma / Stage IV Melanoma1
2Active Not RecruitingTreatmentRecurrent Uveal Melanoma / Stage III Uveal Melanoma / Stage IIIA Uveal Melanoma / Stage IIIB Uveal Melanoma / Stage IIIC Uveal Melanoma / Stage IV Uveal Melanoma1
2Active Not RecruitingTreatmentTumors, Central Nervous System1
2CompletedTreatmentAdult Giant Cell Glioblastoma / Adult Glioblastoma / Adult Gliosarcoma1
2CompletedTreatmentAdult Glioblastoma / Adult Gliosarcoma1
2CompletedTreatmentAdult Glioblastoma / Adult Gliosarcoma / Recurrent Adult Brain Tumor1
2CompletedTreatmentAdult Rhabdomyosarcoma / Childhood Alveolar Rhabdomyosarcoma / Childhood Embryonal Rhabdomyosarcoma / Metastatic Childhood Soft Tissue Sarcoma / Stage IV Adult Soft Tissue Sarcoma / Untreated Childhood Rhabdomyosarcoma1
2CompletedTreatmentAnaplastic Astrocytoma (AA) / Glioblastomas1
2CompletedTreatmentAnaplastic Glioma of Brain / Brain Cancer / Glioblastoma Multiforme1
2CompletedTreatmentAnaplastic Gliomas / Glioblastoma Multiforme1
2CompletedTreatmentAnaplastic Oligoastrocytoma / Anaplastic Oligodendroglioma (AO)1
2CompletedTreatmentAnaplastic Oligodendroglioma (AO) / Oligoastrocytoma, Mixed1
2CompletedTreatmentAstrocytomas1
2CompletedTreatmentAstrocytomas / Brain Tumor, Recurrent / Glioblastomas / Oligodendrogliomas1
2CompletedTreatmentAstrocytomas / Glioblastomas / Gliomas / Oligodendrogliomas1
2CompletedTreatmentAstrocytomas / Gliomas / Oligodendrogliomas1
2CompletedTreatmentBrain and Central Nervous System Tumors19
2CompletedTreatmentBrain and Central Nervous System Tumors / Neuroblastomas1
2CompletedTreatmentBrain and Central Nervous System Tumors / Unspecified Adult Solid Tumor, Protocol Specific1
2CompletedTreatmentCNS Tumor, Adult2
2CompletedTreatmentCancer, Breast / Metastatic Cancers1
2CompletedTreatmentCancer, Breast / Soft Tissue Sarcoma (STS)1
2CompletedTreatmentCancer, Ovarian1
2CompletedTreatmentCancer, Ovarian / Testicular germ cell tumour1
2CompletedTreatmentCancers / Melanoma / Skin Cancers1
2CompletedTreatmentCancers / Metastatic Brain Tumors1
2CompletedTreatmentCentral Nervous System Tumor, Pediatric1
2CompletedTreatmentCentral Nervous System Tumor, Pediatric / Neuroblastomas1
2CompletedTreatmentColorectal Cancers1
2CompletedTreatmentGastroenteropancreatic Neuroendocrine Tumors1
2CompletedTreatmentGastrointestinal Stromal Tumors1
2CompletedTreatmentGlioblastoma Multiforme15
2CompletedTreatmentGlioblastoma Multiforme / Gliosarcoma2
2CompletedTreatmentGlioblastoma Multiforme / Primary Brain Tumors1
2CompletedTreatmentGlioblastomas6
2CompletedTreatmentGlioblastomas / Gliomas1
2CompletedTreatmentGlioblastomas / Gliosarcoma4
2CompletedTreatmentGlioblastomas / Gliosarcoma / Neoplasms, Brain1
2CompletedTreatmentGlioblastomas / Primary Brain Tumors1
2CompletedTreatmentGliomas3
2CompletedTreatmentGliomas / Medulloblastomas1
2CompletedTreatmentHigh Grade Gliomas / Neoplasms, Brain1
2CompletedTreatmentIntraocular Melanoma / Melanoma (Skin)2
2CompletedTreatmentLeukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndrome1
2CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Melanoma / Metastases of Central Nervous System / Neoplasms, Breast1
2CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Neoplasms Metastasis / Neoplasms, Brain1
2CompletedTreatmentLung Cancers5
2CompletedTreatmentLung Cancers / Metastatic Cancers2
2CompletedTreatmentMalignant Gliomas1
2CompletedTreatmentMalignant Lymphomas2
2CompletedTreatmentMalignant Melanoma1
2CompletedTreatmentMalignant Neoplasms of Brain1
2CompletedTreatmentMedulloblastomas1
2CompletedTreatmentMelanoma4
2CompletedTreatmentMelanoma (Skin)5
2CompletedTreatmentMelanoma / Metastatic Melanoma / Skin Cancers1
2CompletedTreatmentMelanoma / Skin Cancers1
2CompletedTreatmentMetastatic Brain Tumors1
2CompletedTreatmentMetastatic Cancers1
2CompletedTreatmentMetastatic Melanoma1
2CompletedTreatmentMyeloid Leukemias1
2CompletedTreatmentNaive Unresectable Glioblastoma1
2CompletedTreatmentNeoplasms, Brain2
2CompletedTreatmentNeoplasms, Brain / Neuroblastomas / Tumors, Solid1
2CompletedTreatmentNeuroblastomas2
2CompletedTreatmentNeuroendocrine Tumors3
2CompletedTreatmentRecurrent Central Nervous System Neoplasm1
2CompletedTreatmentRecurrent Glioblastoma Multiforme2
2CompletedTreatmentRecurrent Glioblastoma Multiforme / Recurrent Gliosarcoma1
2CompletedTreatmentRecurrent Melanoma / Stage IV Melanoma / Tumors Metastatic to Brain1
2CompletedTreatmentRecurrent Small Cell Lung Carcinoma1
2CompletedTreatmentSolid Tumor Cancers1
2Enrolling by InvitationTreatmentLung Cancer Small Cell Lung Cancer (SCLC) / Metastatic Carcinoma1
2Not Yet RecruitingTreatmentBrain Metastasis / Radiation Therapy Complication1
2Not Yet RecruitingTreatmentCapecitabine / Neuroendocrine Carcinomas / Neuroendocrine Tumors / Temozolomide1
2Not Yet RecruitingTreatmentGlioblastoma Multiforme1
2Not Yet RecruitingTreatmentGlioblastomas1
2RecruitingDiagnosticAdult Anaplastic (Malignant) Meningioma / Adult Anaplastic Astrocytoma / Adult Anaplastic Ependymoma / Adult Brain Stem Glioma / Adult Choroid Plexus Neoplasm / Adult Ependymoblastoma / Adult Giant Cell Glioblastoma / Adult Glioblastoma / Adult Gliosarcoma / Adult Medulloblastoma / Adult Mixed Glioma / Adult Papillary Meningioma / Adult Pineal Gland Astrocytoma / Adult Pineoblastoma / Adult Primary Melanocytic Lesion of Meninges / Adult Supratentorial Primitive Neuroectodermal Tumor / Malignant Gliomas1
2RecruitingTreatment1p/19q Co-deletion / Anaplastic Astrocytoma (AA) / Diffuse Astrocytoma / Gliomas / IDH1 Gene Mutation / IDH2 Gene Mutation / Oligoastrocytoma / Oligodendrogliomas / WHO Grade III Glioma1
2RecruitingTreatmentAdult Giant Cell Glioblastoma / Adult Glioblastoma / Adult Gliosarcoma1
2RecruitingTreatmentAdvanced Malignant Solid Neoplasm / Neoplasms / Neoplasms, Advanced Solid / Recurrent Malignant Solid Neoplasm / Recurrent Solid Neoplasm1
2RecruitingTreatmentAstrocytoma, Grade IV / Giant Cell Glioblastoma / Glioblastoma Multiforme / Glioblastomas1
2RecruitingTreatmentAstrocytomas / Oligoastrocytoma / Oligodendrogliomas1
2RecruitingTreatmentB-Cell Lymphoma Originating in the CNS1
2RecruitingTreatmentChildhood Brain Stem Neoplasm1
2RecruitingTreatmentColorectal Large Cell Neuroendocrine Carcinoma / Esophageal Large Cell Neuroendocrine Carcinoma / Gallbladder Large Cell Neuroendocrine Carcinoma / Gastric Large Cell Neuroendocrine Carcinoma / Pancreatic Large Cell Neuroendocrine Carcinoma / Small Intestinal Large Cell Neuroendocrine Carcinoma1
2RecruitingTreatmentEpendymomas / Ewing's Sarcoma (ES) / Gliomas / Medulloblastomas / Neuroectodermal Tumors / Rhabdomyosarcomas / Sarcoma, Osteogenic / Wilms' tumor1
2RecruitingTreatmentEwing's Sarcoma (ES)1
2RecruitingTreatmentExtensive Stage Small Cell Lung Cancer1
2RecruitingTreatmentExtrapancreatic Neuroendocrine Tumor1
2RecruitingTreatmentGlioblastoma Multiforme5
2RecruitingTreatmentGlioblastoma Multiforme of Brain1
2RecruitingTreatmentGlioblastomas5
2RecruitingTreatmentGlioblastomas / Gliosarcoma3
2RecruitingTreatmentGlioblastomas / Gliosarcoma / Supratentorial Glioblastoma1
2RecruitingTreatmentGlioblastomas / Recurrent Glioblastoma1
2RecruitingTreatmentGliomas2
2RecruitingTreatmentHigh Grade Glioma (HGG)1
2RecruitingTreatmentLow Grade Glioma (LGG) / Oligoastrocytoma, Mixed / Oligodendrogliomas / WHO Grade II Astrocytomas1
2RecruitingTreatmentMedulloblastomas1
2RecruitingTreatmentMetastatic Colorectal Cancers1
2RecruitingTreatmentMidgut Neuroendocrine Tumours / Progressive Neuroendocrine Tumors of pancreatic origin1
2RecruitingTreatmentNeuroblastoma Recurrent1
2RecruitingTreatmentNeuroblastomas1
2RecruitingTreatmentNeuroendocrine Carcinomas1
2RecruitingTreatmentNeuroendocrine Tumors1
2RecruitingTreatmentNeuroendocrine Tumours1
2RecruitingTreatmentNewly Diagnosed Ewing Sarcoma1
2RecruitingTreatmentPinealoblastoma1
2RecruitingTreatmentPrimary Central Nervous System Lymphoma (PCNSL)2
2RecruitingTreatmentProgressive Neuroendocrine Tumors of pancreatic origin1
2RecruitingTreatmentRhabdomyosarcomas1
2RecruitingTreatmentRefractory Small cell lung cancer1
2SuspendedTreatmentGanglioneuroblastoma / Recurrent Neuroblastoma1
2TerminatedDiagnosticMalignant Gliomas1
2TerminatedPreventionNeoplasms, Brain / Neoplasms, Breast / Second Neoplasm1
2TerminatedTreatmentAdenocarcinomas / Carcinoma, Large Cell / Lung Cancer Non-Small Cell Cancer (NSCLC) / Squamous Cell Carcinoma (SCC)1
2TerminatedTreatmentAstrocytomas / Gliomas / Oligoastrocytoma / Oligodendrogliomas1
2TerminatedTreatmentBone Cancer / Ewing's Sarcoma (ES)1
2TerminatedTreatmentBrain Cancer1
2TerminatedTreatmentBrain and Central Nervous System Tumors1
2TerminatedTreatmentGlioblastoma Multiforme2
2TerminatedTreatmentGlioblastoma Multiforme / High-Grade Gliomas1
2TerminatedTreatmentGlioblastomas1
2TerminatedTreatmentGlioblastomas / Gliosarcoma1
2TerminatedTreatmentGliomas1
2TerminatedTreatmentHepatocellular,Carcinoma1
2TerminatedTreatmentLeptomeningeal Metastases / Neoplasms, Brain / Tumors, Central Nervous System1
2TerminatedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
2TerminatedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Neoplasm Metastases / Neoplasms, Brain1
2TerminatedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Neoplasms, Colorectal / Neoplasms, Esophageal / Neoplasms, Head and Neck1
2TerminatedTreatmentMalignant Lymphomas1
2TerminatedTreatmentMalignant Melanoma1
2TerminatedTreatmentMelanoma2
2TerminatedTreatmentMelanoma (Skin)1
2TerminatedTreatmentMelanoma (Skin) / Metastatic Cancers1
2TerminatedTreatmentMetastatic Brain Tumors1
2TerminatedTreatmentRetinoblastoma1
2TerminatedTreatmentUnresectable Stage III Melanoma / Wild Type BRAF Stage IV Melanoma1
2Unknown StatusTreatmentBrain and Central Nervous System Tumors6
2Unknown StatusTreatmentCancer, Breast1
2Unknown StatusTreatmentCancer, Breast / Metastatic Cancers1
2Unknown StatusTreatmentCancer, Ovarian / Endometrial Cancers / Sarcomas1
2Unknown StatusTreatmentCentral Nervous System (CNS) Metastases / Metastatic Brain Tumors1
2Unknown StatusTreatmentGlioblastomas2
2Unknown StatusTreatmentGliomas2
2Unknown StatusTreatmentHigh-Grade Gliomas1
2Unknown StatusTreatmentIntraocular Melanoma1
2Unknown StatusTreatmentLung Cancer and Breast Cancer Patients With Brain Metastases1
2Unknown StatusTreatmentMalignant Gliomas1
2Unknown StatusTreatmentMalignant Lymphomas1
2Unknown StatusTreatmentMalignant Melanoma1
2Unknown StatusTreatmentMelanoma1
2Unknown StatusTreatmentMelanoma (Skin)1
2Unknown StatusTreatmentNewly Diagnosed Non Methylated Glioblastoma Multiforme Grade 41
2Unknown StatusTreatmentNewly Diagnosed Supratentorial Malignant Glioma1
2Unknown StatusTreatmentPrimary Central Nervous System Lymphoma (PCNSL)1
2Unknown StatusTreatmentSarcomas1
2Unknown StatusTreatmentTumors, Central Nervous System2
2WithdrawnTreatmentBrain Diseases / CNS Disease / Glioblastomas1
2WithdrawnTreatmentBrain and Central Nervous System Tumors2
2WithdrawnTreatmentBrain and Central Nervous System Tumors / Neuroblastomas / Retinoblastoma / Sarcomas1
2WithdrawnTreatmentCancer, Ovarian1
2WithdrawnTreatmentGlioblastomas / Gliosarcoma1
2WithdrawnTreatmentLung Cancers / Metastatic Cancers1
2WithdrawnTreatmentMelanoma / Neoplasms, Brain1
2WithdrawnTreatmentSoft Tissue Sarcoma (STS)1
2, 3Active Not RecruitingTreatmentEpendymomas / Medulloblastomas / Recurrent Brain Tumors / Supratentorial PNETs1
2, 3CompletedTreatmentBrain Stem Gliomas / Cerebral Astrocytoma / Childhood Cerebellar Anaplastic Astrocytoma / Childhood Cerebral Anaplastic Astrocytoma / Childhood Spinal Cord Neoplasm / Untreated Childhood Brain Stem Glioma / Untreated Childhood Cerebral Astrocytoma1
2, 3Not Yet RecruitingTreatmentGlioblastomas1
2, 3RecruitingTreatmentAnaplastic Astrocytoma (AA) / Glioblastoma Multiforme1
2, 3RecruitingTreatmentExtensive-Stage Small Cell Lung Cancer1
2, 3RecruitingTreatmentGlioblastomas / Gliosarcoma1
3Active Not RecruitingTreatmentAdult Giant Cell Glioblastoma / Adult Glioblastoma / Adult Gliosarcoma / Cognitive Side Effects of Cancer Therapy1
3Active Not RecruitingTreatmentBrain and Central Nervous System Tumors1
3CompletedTreatmentAnaplastic Astrocytoma (AA) / Glioblastomas1
3CompletedTreatmentAnaplastic Astrocytoma (AA) / Oligoastrocytoma / Oligodendrogliomas1
3CompletedTreatmentAstrocytomas / Glioblastomas1
3CompletedTreatmentBrain and Central Nervous System Tumors5
3CompletedTreatmentGiant Cell Glioblastoma / Glioblastoma With Oligodendroglial Component / Glioblastomas / Gliosarcoma / Small Cell Glioblastoma1
3CompletedTreatmentGlioblastoma Multiforme1
3CompletedTreatmentGlioblastomas5
3CompletedTreatmentMelanoma2
3CompletedTreatmentMetastatic Melanoma1
3Not Yet RecruitingTreatmentAnaplastic Astrocytoma WHO Grade III / Diffuse Intrinsic Pontine Glioma (DIPG) / Diffuse Midline Glioma Histone 3 K27M WHO Grade IV / Glioblastoma WHO Grade IV / Gliomatosis Cerebri1
3RecruitingTreatmentAnaplastic Astrocytoma (AA) / Anaplastic Oligoastrocytoma / Glioblastomas1
3RecruitingTreatmentAstrocytomas / Oligodendroastrocytoma / Oligodendrogliomas1
3RecruitingTreatmentBrain Cancer1
3RecruitingTreatmentBrain and Central Nervous System Tumors1
3RecruitingTreatmentBrain and Central Nervous System Tumors / Neurotoxicity1
3RecruitingTreatmentGlioblastomas1
3RecruitingTreatmentGlioblastomas / Progression / Recurrences1
3RecruitingTreatmentNeoplasms, Brain1
3RecruitingTreatmentPrimary Central Nervous System Lymphoma (PCNSL)1
3SuspendedTreatmentBrain Cancer / Choroid Plexus Tumors1
3TerminatedTreatmentAnaplastic Astrocytoma (AA) / Glioblastomas1
3TerminatedTreatmentAstrocytomas / Oligoastrocytoma / Oligodendrogliomas1
3TerminatedTreatmentGlioblastoma Multiforme1
3TerminatedTreatmentMelanoma (Skin) / Metastatic Cancers1
3TerminatedTreatmentRecurrent Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer / Tumors Metastatic to Brain1
3Unknown StatusNot AvailableLung Cancer Non-Small Cell Cancer (NSCLC) / Neoplasms Metastasis1
3Unknown StatusTreatmentBrain and Central Nervous System Tumors1
3WithdrawnTreatmentOptic Nerve Glioma1
3WithdrawnTreatmentRecurrent Glioblastoma1
4CompletedTreatmentBrain Neoplasms, Malignant, Primary1
4CompletedTreatmentGlioblastomas1
4Not Yet RecruitingNot AvailableAdvanced Milignant Gliomas / Cytokine-Induced Killer Cells1
Not AvailableActive Not RecruitingTreatmentAdult Giant Cell Glioblastoma / Adult Glioblastoma / Adult Gliosarcoma / Giant Cell Glioblastoma / Glioblastomas / Gliosarcoma1
Not AvailableActive Not RecruitingTreatmentRecurrent Childhood Brain Tumor1
Not AvailableCompletedNot AvailableAstrocytomas / Glioblastomas / Gliomas1
Not AvailableCompletedNot AvailableAstrocytomas / Gliomas1
Not AvailableCompletedNot AvailableGlioblastomas3
Not AvailableCompletedDiagnosticAdult Glioblastoma / Depression / Recurrent Adult Brain Tumor1
Not AvailableCompletedTreatmentBrain and Central Nervous System Tumors1
Not AvailableCompletedTreatmentBrain and Central Nervous System Tumors / Malignant Lymphomas1
Not AvailableCompletedTreatmentBrain and Central Nervous System Tumors / Metastatic Cancers1
Not AvailableCompletedTreatmentGlioblastoma Mutliforme1
Not AvailableCompletedTreatmentNeoplasms, Brain / Tumors, Central Nervous System1
Not AvailableNot Yet RecruitingTreatmentRecurrent High-grade Glioma1
Not AvailableTerminatedNot AvailableBrain and Central Nervous System Tumors1
Not AvailableTerminatedNot AvailableGlioblastomas1
Not AvailableUnknown StatusTreatmentBrain and Central Nervous System Tumors / Thrombocytopenias1
Not AvailableWithdrawnNot AvailableAstrocytoma, Grade IV / Giant Cell Glioblastoma / Glioblastoma Multiforme1
Not AvailableWithdrawnTreatmentMalignant Lymphomas / Tumors, Central Nervous System1

Pharmacoeconomics

Manufacturers
  • Schering corp
  • Barr laboratories inc
Packagers
Dosage forms
FormRouteStrength
CapsuleOral180 mg
CapsuleOral100 mg
CapsuleOral140 mg
CapsuleOral20 mg
CapsuleOral250 mg
CapsuleOral5 mg
Injection, powder, for solutionIntravenous2.5 mg/ml
Powder, for solutionIntravenous100 mg
CapsuleOral100 mg/1
CapsuleOral180 mg/1
CapsuleOral20 mg/1
CapsuleOral250 mg/1
CapsuleOral5 mg/1
Injection, powder, lyophilized, for solutionIntravenous2.5 mg/mL
CapsuleOral140 mg/1
CapsuleOral180 1/1
Prices
Unit descriptionCostUnit
Temodar 250 mg capsule466.11USD capsule
Temodar 180 mg capsule401.53USD capsule
Temodar 100 mg capsule223.07USD capsule
Temodar 20 mg capsule44.62USD capsule
Temodar 5 mg capsule10.84USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5260291No1993-08-112013-08-11Us
CA2476494No2010-04-272023-02-20Canada
CA2066313No2002-08-202012-04-16Canada
US6987108No2003-09-082023-09-08Us
US7786118No2003-02-212023-02-21Us
US8623868No2003-02-212023-02-21Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)212 °CNot Available
logP-2.8Not Available
Predicted Properties
PropertyValueSource
Water Solubility5.09 mg/mLALOGPS
logP-1ALOGPS
logP-0.28ChemAxon
logS-1.6ALOGPS
pKa (Strongest Acidic)10.51ChemAxon
pKa (Strongest Basic)-3.6ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area105.94 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity47.86 m3·mol-1ChemAxon
Polarizability16.88 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9879
Caco-2 permeable+0.5608
P-glycoprotein substrateNon-substrate0.7228
P-glycoprotein inhibitor INon-inhibitor0.9255
P-glycoprotein inhibitor IINon-inhibitor0.9823
Renal organic cation transporterNon-inhibitor0.8822
CYP450 2C9 substrateNon-substrate0.7948
CYP450 2D6 substrateNon-substrate0.8695
CYP450 3A4 substrateNon-substrate0.5855
CYP450 1A2 substrateNon-inhibitor0.8134
CYP450 2C9 inhibitorNon-inhibitor0.9753
CYP450 2D6 inhibitorNon-inhibitor0.9479
CYP450 2C19 inhibitorNon-inhibitor0.9522
CYP450 3A4 inhibitorNon-inhibitor0.9571
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9954
Ames testNon AMES toxic0.5322
CarcinogenicityNon-carcinogens0.9412
BiodegradationNot ready biodegradable0.5172
Rat acute toxicity2.5279 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7553
hERG inhibition (predictor II)Non-inhibitor0.9242
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as imidazotetrazines. These are organic polycyclic compounds containing an imidazole ring fused to a tetrazine ring. Imidazole is 5-membered ring consisting of three carbon atoms, and two nitrogen centers at the 1- and 3-positions. Tetrazine is a six-membered aromatic heterocycle made up of four nitrogen atoms and a two carbon atoms.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Imidazotetrazines
Sub Class
Not Available
Direct Parent
Imidazotetrazines
Alternative Parents
2-heteroaryl carboxamides / Carbonylimidazoles / Tetrazines / N-substituted imidazoles / Vinylogous amides / Heteroaromatic compounds / Primary carboxylic acid amides / Azacyclic compounds / Organopnictogen compounds / Organooxygen compounds
show 3 more
Substituents
Imidazotetrazine / 2-heteroaryl carboxamide / Imidazole-4-carbonyl group / N-substituted imidazole / Tetrazine / Azole / Imidazole / Heteroaromatic compound / Vinylogous amide / Carboxamide group
show 11 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
monocarboxylic acid amide, triazene derivative, imidazotetrazine (CHEBI:72564)

Targets

1. DNA
Kind
Nucleotide
Organism
Human
Pharmacological action
Yes
Actions
Cross-linking/alkylation
General Function:
Used for biological information storage.
Specific Function:
DNA contains the instructions needed for an organism to develop, survive and reproduce.
Molecular Weight:
2.15 x 1012 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Zaremba T, Curtin NJ: PARP inhibitor development for systemic cancer targeting. Anticancer Agents Med Chem. 2007 Sep;7(5):515-23. [PubMed:17896912]
  4. Dinca EB, Sarkaria JN, Schroeder MA, Carlson BL, Voicu R, Gupta N, Berger MS, James CD: Bioluminescence monitoring of intracranial glioblastoma xenograft: response to primary and salvage temozolomide therapy. J Neurosurg. 2007 Sep;107(3):610-6. [PubMed:17886562]
  5. Marchesi F, Turriziani M, Tortorelli G, Avvisati G, Torino F, De Vecchis L: Triazene compounds: mechanism of action and related DNA repair systems. Pharmacol Res. 2007 Oct;56(4):275-87. Epub 2007 Aug 9. [PubMed:17897837]
  6. Neyns B, Tosoni A, Hwu WJ, Reardon DA: Dose-dense temozolomide regimens: antitumor activity, toxicity, and immunomodulatory effects. Cancer. 2010 Jun 15;116(12):2868-77. doi: 10.1002/cncr.25035. [PubMed:20564393]
  7. Wick W, Platten M, Weller M: New (alternative) temozolomide regimens for the treatment of glioma. Neuro Oncol. 2009 Feb;11(1):69-79. doi: 10.1215/15228517-2008-078. Epub 2008 Sep 4. [PubMed:18772354]
  8. Natelson EA, Pyatt D: Temozolomide-induced myelodysplasia. Adv Hematol. 2010;2010:760402. doi: 10.1155/2010/760402. Epub 2010 Mar 4. [PubMed:20224797]
  9. Friedman HS, Kerby T, Calvert H: Temozolomide and treatment of malignant glioma. Clin Cancer Res. 2000 Jul;6(7):2585-97. [PubMed:10914698]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Drug created on June 13, 2005 07:24 / Updated on November 19, 2017 20:33